Compare COR & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COR | BDX |
|---|---|---|
| Founded | 2001 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1B | 54.6B |
| IPO Year | 2001 | 1998 |
| Metric | COR | BDX |
|---|---|---|
| Price | $339.53 | $212.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $371.67 | $195.57 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | 0.75% | ★ 2.01% |
| EPS Growth | ★ 5.71 | N/A |
| EPS | ★ 15.21 | 1.59 |
| Revenue | ★ $321,332,819,000.00 | $21,840,000,000.00 |
| Revenue This Year | $4.89 | N/A |
| Revenue Next Year | $4.35 | $2.27 |
| P/E Ratio | ★ $23.27 | $131.56 |
| Revenue Growth | ★ 9.31 | 8.24 |
| 52 Week Low | $244.82 | $140.11 |
| 52 Week High | $377.54 | $213.08 |
| Indicator | COR | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 71.19 | 74.35 |
| Support Level | $299.24 | $175.60 |
| Resistance Level | $375.91 | $213.08 |
| Average True Range (ATR) | 7.60 | 3.89 |
| MACD | 1.04 | 0.79 |
| Stochastic Oscillator | 95.39 | 96.83 |
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.